Table 2 Prevalence and characteristics of antipsychotic medication in AN
Total (n = 44) | |
|---|---|
Prevalence of antipsychotics | M ± SD N (%) |
Antipsychotics, average number | 1.2 ± 0.6 |
One antipsychotic | 37 (84.1) |
Two antipsychotics | 6 (13.6) |
Three antipsychotics | 0 (0) |
Four antipsychotics | 1 (2.3) |
Total number of antipsychotic trials | 52 (100) |
Typical antipsychotics, number | 13 (25.0) |
Chlorprothixene, number | 11 (21.2) |
Pipamperone, number | 1 (1.9) |
Thioridazine, number | 1 (1.9) |
Atypical antipsychotics, number | 39 (75.0) |
Olanzapine, number | 33 (63.5) |
Quetiapine, number | 5 (9.6) |
Risperidone, number | 1 (1.9) |
Characteristics of antipsychotics | M ± SD N (%) |
Start week of antipsychotics, number | 5.9 ± 3.8 |
End week of antipsychotics, number | 12.7 ± 5.5 |
Duration of antipsychotics, average weeks | 6.8 ± 4.0 |
Duration of antipsychotics, percentage of treatment duration, average weeks | 43.0 ± 25.0 |
Duration of treatment weeks after antipsychotics offset | 6.0 ± 6.9 |
Maximum dose of antipsychotics, mg (CPZ equivalents) | 34.5 ± 75.2 |
End dose of antipsychotics, mg (CPZ equivalents) | 34.7 ± 89.7 |
Antipsychotics after discharge | 26 (59.1) |
Changing/ending antipsychotic medication | M ± SD N (%) |
Reasons for changing/ending antipsychotics | 15 (34.1) |
Inefficiency | 6 (13.6) |
Intolerability | 4 (9.1) |
No longer needed | 4 (9.1) |
Patient or parent request | 1 (2.3) |
Other | 0 (0) |